At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Aug 6, 2026 at 06:50 ET
Pharvaris announced publication of the first in-depth qualitative study in AAE-C1INH in Frontiers in Immunology, validating PRO measures and directly informing endpoint selection for the ongoing Phase 3 CREAATE study of deucrictibant. There are currently no approved therapies for this ultra-rare, serious disease. This is a scientific milestone that supports the regulatory path but does not change the stock's near-term fundamentals.
- First in-depth qualitative study in AAE-C1INH published in peer-reviewed journal Frontiers in Immunology.
- Study validates PGI-C, PGI-S, and PGA as meaningful PRO instruments for this indication.
- Findings directly informed design and endpoint selection for the ongoing Phase 3 CREAATE study (NCT07266805) of deucrictibant.
- No approved therapies exist for prevention or treatment of AAE-C1INH attacks, all patients currently rely on off-label therapies.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access